A study presented at the European Society for Medical Oncology Congress 2024 found that adding nivolumab to rucaparib did not improve progression-free survival in patients with advanced high-grade ovarian cancer. The study compared the combination therapy to rucaparib monotherapy and found the combination was associated with shorter PFS. The study enrolled 863 patients across 24 countries. While the results were disappointing, they provide valuable insights for future research. However, safety concerns were noted with the combination therapy, leading to a higher rate of treatment discontinuation and more adverse events compared to monotherapy, potentially compromising efficacy. Future research is needed to explore other combination strategies in ovarian cancer treatment.
Source link
Worse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
